ciprofibrate has been researched along with Graves Disease in 1 studies
Graves Disease: A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonelli, A | 1 |
| Ferrari, SM | 1 |
| Frascerra, S | 1 |
| Corrado, A | 1 |
| Pupilli, C | 1 |
| Bernini, G | 1 |
| Benvenga, S | 1 |
| Ferrannini, E | 1 |
| Fallahi, P | 1 |
1 other study available for ciprofibrate and Graves Disease
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease.
Topics: Antiviral Agents; Cells, Cultured; Chemokine CCL2; Chemokine CXCL10; Enzyme-Linked Immunosorbent Ass | 2011 |